Auto-injector

Information

  • Patent Grant
  • 12090303
  • Patent Number
    12,090,303
  • Date Filed
    Friday, March 29, 2024
    7 months ago
  • Date Issued
    Tuesday, September 17, 2024
    a month ago
Abstract
An auto-injector for administering a dose of a liquid medicament includes an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament, the housing having a distal end and a proximal end with an orifice intended to be applied against an injection site. The syringe is slidably arranged with respect to the housing. A spring capable of, upon activation: pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal end (P), operating the syringe to supply the dose of medicament (M), and retracting the syringe with the needle into the covered position. After delivering the medicament, an activator arranged to lock the spring in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring for injection.
Description
TECHNICAL FIELD

The invention relates to an auto-injector for administering a dose of a liquid medicament according to the preamble of claim 1.


BACKGROUND OF THE INVENTION

Administering an injection is a process which presents a number of risks and challenges for users and healthcare professionals, both mental and physical.


Injection devices (i.e. devices capable of delivering medicaments from a medication container) typically fall into two categories—manual devices and auto-injectors.


In a manual device—the user must provide the mechanical energy to drive the fluid through the needle. This is typically done by some form of button/plunger that has to be continuously pressed by the user during the injection. There are numerous disadvantages to the user from this approach. If the user stops pressing the button/plunger then the injection will also stop. This means that the user can deliver an underdose if the device is not used properly (i.e. the plunger is not fully pressed to its end position). Injection forces may be too high for the user, in particular if the patient is elderly or has dexterity problems.


The extension of the button/plunger may be too great. Thus it can be inconvenient for the user to reach a fully extended button. The combination of injection force and button extension can cause trembling/shaking of the hand which in turn increases discomfort as the inserted needle moves.


Auto-injector devices aim to make self-administration of injected therapies easier for patients. Current therapies delivered by means of self-administered injections include drugs for diabetes (both insulin and newer GLP-1 class drugs), migraine, hormone therapies, anticoagulants etc.


Auto-injectors are devices which completely or partially replace activities involved in parenteral drug delivery from standard syringes. These activities may include removal of a protective syringe cap, insertion of a needle into a patient's skin, injection of the medicament, removal of the needle, shielding of the needle and preventing reuse of the device. This overcomes many of the disadvantages of manual devices. Injection forces/button extension, hand-shaking and the likelihood of delivering an incomplete dose are reduced. Triggering may be performed by numerous means, for example a trigger button or the action of the needle reaching its injection depth. In some devices the energy to deliver the fluid is provided by a spring.


US 2002/0095120 A1 discloses an automatic injection device which automatically injects a pre-measured quantity of fluid medicine when a tension spring is released. The tension spring moves an ampoule and the injection needle from a storage position to a deployed position when it is released. The content of the ampoule is thereafter expelled by the tension spring forcing a piston forward inside the ampoule. After the fluid medicine has been injected, torsion stored in the tension spring is released and the injection needle is automatically retracted back to its original storage position.


US 2007/0112310 A1 discloses an injector being automatic in that the needle is inserted into the injection site (e.g., a patient's skin) with user or caregiver assistance, the delivery is automatically initiated upon needle insertion, and the needle is retracted automatically after the end of delivery. Preferably the needle is not seen by the user prior to, during or after injection. Prior to and after injection, the needle is hidden in the device so as to avoid any potential injury or health risk to the user or health care provider. The injector includes a housing and a shield arranged to slide relative to the housing and a driver moving during drug delivery. The housing and shield form a cartridge enclosure. The cartridge is shielded and locked after delivery is completed. A needle-locking mechanism can be used in any number of pen-like injectors or safety needles.


U.S. Pat. No. 5,267,963 discloses an automatic injection device which, upon activation by the user, automatically extends a syringe with needle, delivers medication through the needle, and retracts the needle, thus keeping the needle hidden from view. All motions are achieved by means of a tension spring and a cam profile.


WO 2009/081103 A1 discloses an auto-injector for a syringe that is suitable for use in the injected delivery of drug to a patient. The auto-injector comprises a housing defining a housing cavity arranged for receipt of a syringe; and a needle delivery aperture through which a needle tip of the syringe protrudes during dispensing of the liquid drug formulation. The auto-injector further comprises a barrel coupling element that couples to the barrel of the syringe and is movable in tandem therewith; a syringe advancer for moving the syringe and barrel coupling element in tandem therewith from a rest position, in which the hollow needle, is within the housing to a use position, in which the needle tip protrudes through the needle delivery aperture; a syringe actuator for actuating the syringe by plunging said plunger within the barrel of the syringe to dispense the liquid drug formulation; a syringe retractor for retracting the syringe and barrel coupling element in tandem therewith from the use position to a retract position, in which the hollow needle is within the housing; and a syringe lock for locking the barrel coupling element and syringe coupled thereto in the retract position.


WO 2008/155377 discloses an inserter for an infusion set comprising an insertion needle and a spring unit assuring automatic insertion and automatic retraction of the insertion needle. The inserter for a medical device comprises—a housing, —a first body which is movable relative to the housing and comprising penetrating means pointing in the direction of insertion, —a second body which is also movable relative to the housing and—driving means which move respectively the first body and the second body relative to the housing wherein the driving means moves the first body in the direction of insertion and moves the second body in a direction different from the insertion direction.


DE 10 2005 038 933 A1 discloses an inserter for an infusion set comprising an insertion needle and a spring unit assuring automatic insertion and automatic retraction of the insertion needle. The inserter for a medical device comprises—a housing, —a first body which is movable relative to the housing and comprising penetrating means pointing in the direction of insertion, —a second body which is also movable relative to the housing and—driving means which move respectively the first body and the second body relative to the housing wherein the driving means moves the first body in the direction of insertion and moves the second body in a direction different from the insertion direction.


SUMMARY OF THE INVENTION

It is an object of the present invention to provide an improved auto-injector.


The object is achieved by an auto-injector according to claim 1.


Preferred embodiments of the invention are given in the dependent claims.


According to the invention, an auto-injector for administering a dose of a liquid medicament comprises:

    • an elongate housing arranged to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament, the housing having a distal end and a proximal end with an orifice intended to be applied against an injection site, wherein the syringe is slidably arranged with respect to the housing,
    • spring means capable of, upon activation:
      • pushing the needle from a covered position inside the housing into an advanced position through the orifice and past the proximal end,
      • operating the syringe to supply the dose of medicament, and
      • retracting the syringe with the needle into the covered position after delivering the medicament,
    • activating means arranged to lock the spring means in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring means for injection.


In the context of this patent application the term proximal refers to the direction pointing towards the patient during an injection while the term distal refers to the opposite direction pointing away from the patient.


According to the invention the spring means is a single compression spring arranged to be grounded at a distal end in the housing for advancing the needle and for injecting the dose of medicament. The force of the compression spring is forwarded to the needle and/or the syringe via a plunger. The compression spring is arranged to have its ground in the housing switched to its proximal end for retracting the syringe when the injection of the medicament is at least nearly finished.


The single compression spring is used for inserting the needle, fully emptying the syringe and retracting the syringe and needle to a safe position after injection. Thus a second spring for withdrawing the syringe and needle, which is a motion with an opposite sense compared to advancing the syringe and injecting the dose, is not required. While the distal end of the compression spring is grounded the proximal end moves the syringe forward for inserting the needle and carries on to the injection by pushing on the stopper. When the injection is at least nearly finished the compression spring bottoms out at its proximal end, resulting in the proximal end being grounded in the housing. At the same time the distal end of the compression spring is released from its ground in the housing. The compression spring is now pulling the syringe in the opposite direction.


The auto-injector according to the invention has a particularly low part count compared to most conventional auto-injectors. The use of just one compression spring reduces the amount of metal needed and thus consequently reduces weight and manufacturing costs.


In a preferred embodiment of the invention a retraction sleeve is axially movable arranged in the housing. At least one latch is provided for axially fixing the retraction sleeve in a maximum proximal position. The compression spring is arranged inside the retraction sleeve with its distal end bearing against a distal end face of the retraction sleeve and with its proximal end bearing against a thrust face of a decoupling member. The decoupling member is arranged to decouple the latch when being moved in proximal direction nearly into a maximum proximal position. When decoupled the retraction sleeve is allowed to move in distal direction and retract the needle by means of the spring force which is no longer grounded at its distal end.


Preferably the plunger is arranged for pushing the syringe and/or the stopper in proximal direction. At least two resilient decoupling arms are arranged at the decoupling member. The decoupling arms exhibit inner ramped surfaces bearing against a first shoulder of the plunger in proximal direction P. The resilient decoupling arms are supportable by an inner wall of the retraction sleeve in order to prevent the decoupling arms from being flexed outward and slip past the first shoulder. In this state the plunger may be pushed in proximal direction by the decoupling member pushing against the first shoulder in order to insert the needle and inject the dose. At least one aperture is arranged in the retraction sleeve allowing the decoupling arms to be flexed outward by the first shoulder thus allowing the first shoulder to slip through the decoupling arms in proximal direction. This may happen when the injection is at least nearly finished. The decoupled plunger allows the syringe and needle to be retracted since it is no longer bearing against the decoupling member.


The syringe may be arranged for joint axial movement with a syringe holder which is slidably arranged in the retraction sleeve. The syringe holder is provided with at least two resilient syringe holder arms arranged distally, the syringe holder arms having a respective inclined surface for bearing against a second shoulder, which is arranged at the plunger proximally from the first shoulder. The syringe holder arms are supportable by an inner surface of the housing in order to prevent them from being flexed outward. Thus, when the trigger button is pressed the spring force forwarded by the plunger does not yet press against the stopper but against the syringe for forwarding it. Consequently, a so called wet injection is avoided, i.e. the liquid medicament is not leaking out of the hollow needle before the needle is inserted. A widened portion is provided in the housing for allowing the syringe holder arms to flex outwards when the syringe holder has nearly reached a maximum proximal position thus allowing the second shoulder to slip through the syringe holder arms and to switch load of the compression spring from the syringe to the stopper. This allows for defining the moment to start injecting the medicament.


A stud may be arranged at the distal end of the plunger. The retraction sleeve may have two or more resilient arms distally from the end face for holding the stud. The stud and/or the resilient arms have ramp features. Thus the resilient arms may be pushed apart by the stud when the plunger is moved in proximal direction. The activating means comprise a trigger button arranged at the distal end of the auto-injector. The trigger button is axially moveable and has at least two rigid retainers for preventing the resilient arms from being flexed outward when the trigger button is in a maximum distal position. Upon pushing the trigger button in proximal direction the retainers are moved in proximal direction in a manner to allow the resilient arms to be flexed out by the stud biased by the compression spring in proximal direction. Thus the stud is allowed to slip past the resilient arms in proximal direction under load of the compression spring in order to start a needle insertion/injection/retraction cycle. The main advantages of this trigger mechanism are its simplicity, the low part count and a high reliability.


In order to reduce the risk of unintentionally triggering the auto-injector a safety button may be arranged laterally at the housing. The safety button has an interlock for preventing the trigger button from being pushed. The safety button is arranged to pull the interlock outward when operated thus allowing the trigger button to be pushed. For this purpose the safety button may be pivoted in the housing or it may be cast in one piece with the housing in a manner to be pivoted somewhere in the middle so pushing one end inwards causes the other end to be pulled outwards.


Consequently, in order to operate the trigger button the safety button has to be pushed first so the auto-injector cannot be operated unintentionally. Another advantage of the lateral safety button is that the risk of operating the auto-injector in the wrong orientation and injecting into the thumb is reduced.


In a preferred embodiment of the invention a delay box is arranged for slowing down the motion of the retraction sleeve. The latches are arranged to be disengaged by the decoupling member before the stopper has reached a maximum proximal position in the syringe. The apertures are arranged to meet the decoupling arms after the stopper has reached its maximum proximal position by means of the motion of the retraction sleeve. A gap is provided between a front face of the retraction sleeve and the syringe holder in their respective maximum proximal positions. The gap allows the retraction sleeve to travel a distance before retracting the syringe holder so the syringe holder is retracted after the decoupling arms met the apertures.


Triggering the retraction when the stopper exactly reaches the end of its travel is a problem due to tolerances when manufacturing the syringe and stopper. Due to these tolerances the position of the stopper at the end of its travel is not repeatable. Consequently, in some cases the stopper would prematurely bottom out so the retraction would not be triggered at all. In other cases the retraction would be triggered before the stopper bottomed so residual medicament would remain in the syringe.


Releasing the retraction sleeve from the housing a certain amount of time or travel before the stopper bottoms out in the syringe avoids the risk of stalling the retraction by the stopper hitting the end of the syringe prematurely. The damped backward motion of the retraction sleeve due to the delay box allows the plunger and stopper to finish their forward travel so the syringe is entirely emptied. The apertures of the retraction sleeve and the decoupling arms, which are now moving in opposite directions, meet after the stopper and plunger have stopped in order to decouple the decoupling member from the plunger. Due to the gap between the front face and the syringe holder the retraction sleeve is not immediately dragging the syringe back in distal direction when starting to move back. When the retraction sleeve has travelled back far enough to close the gap the stopper has already bottomed out and the plunger has been decoupled from the decoupling member. As soon as the gap is closed the syringe holder, the syringe, the hollow needle and the plunger are dragged back in distal direction.


Thus both problems are solved, reliably retracting the hollow needle to a safe position and fully emptying the syringe which is particularly desirable with expensive drugs. Emptying the syringe is also important for dosage accuracy.


The delay box may comprise a circumferential outer wall with a back collar attached to the housing and a circumferential inner wall with a front collar attached to the retraction sleeve. A volume is defined between the outer wall and inner wall, the volume sealed by the back collar and front collar and filled with a viscous fluid. At least one hole is arranged in the delay box for allowing the viscous fluid to be pushed out as the volume decreases due to motion of the retraction sleeve. This is a particularly simple and cost-efficient way to damp the backward motion of the retraction sleeve.


Usually the hollow needle is equipped with a protective needle shield for keeping the needle sterile and preventing it from being mechanically damaged. The protective needle shield is attached to the needle when the auto-injector or the syringe is assembled.


Preferably a cap is provided at the proximal end of the housing. A sheet metal clip is attached to the cap for joint axial movement and independent rotation. The sheet metal clip is arranged to extend through an orifice into the housing when the cap is attached to the housing. The sheet metal clip comprises at least two barbs snapped into a circumferential notch or behind a shoulder of the protective needle shield. This allows for automatically engaging the sheet metal clip with the protective needle shield during assembly. When the cap is removed from the housing in preparation of an injection the protective needle shield is reliably removed without exposing the user too high a risk to injure themselves.


The cap may be attachable to the housing by a screw connection. This allows for a low force removal of the protective needle shield.


The housing may have at least one viewing window for inspecting the syringe.


The auto-injector may preferably be used for subcutaneous or intra-muscular injection, particularly for delivering one of an analgetic, an anticoagulant, insulin, an insulin derivate, heparin, Lovenox, a vaccine, a growth hormone, a peptide hormone, a proteine, antibodies and complex carbohydrates.


The term “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,

    • wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
    • wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
    • wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
    • wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exedin-3 or exedin-4 or an analogue or derivative of exedin-3 or exedin-4.


Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.


Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(ω-carboxyheptadecanoyl) human insulin.


Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu- Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser- Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.


Exendin-4 derivatives are for example selected from the following list of compounds:

    • H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
    • H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
    • des Pro36 [Asp28] Exendin-4(1-39),
    • des Pro36 [IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
    • des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39); or
    • des Pro36 [Asp28] Exendin-4(1-39),
    • des Pro36 [IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14, Asp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14, IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39),
    • des Pro36 [Trp(O2)25, IsoAsp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14 Trp(O2)25, Asp28] Exendin-4(1-39),
    • des Pro36 [Met(O)14 Trp(O2)25, IsoAsp28] Exendin-4(1-39),
    • wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
    • or an Exendin-4 derivative of the sequence
    • H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
    • des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
    • H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
    • H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
    • des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36 [Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
    • H-des Asp28 Pro36, Pro37, Pro38 [Trp(O2)25] Exendin-4(1-39)-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
    • des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36 [Met(O)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
    • des Met(O)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
    • H-(Lys)6-desPro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
    • des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
    • H-des Asp28 Pro36, Pro37, Pro38 [Met(O)14, Trp(02)25] Exendin-4(1-39)-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1-39)-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-NH2,
    • des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
    • H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
    • H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;


      or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exedin-4 derivative.


Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.


A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.


Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.


Pharmaceutically acceptable solvates are for example hydrates.


The delay box may be employed with other types of auto-injectors.


The cap with the sheet metal spring may also be applied with other auto-injectors and injection devices.


Further scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from the detailed description given herein below and the accompanying drawings which are given by way of illustration only, and thus, are not limiting of the present invention, and wherein:



FIG. 1 are two longitudinal sections of an auto-injector with a single compression spring for advancing a syringe with a needle, injecting a dose of medicament and retracting the syringe and needle, the auto-injector as-delivered,



FIG. 2 are two longitudinal sections of the auto-injector with the syringe and needle advanced and the dose expelled from the syringe,



FIG. 3 is a perspective sectional view of the auto-injector in the initial state of FIG. 1,



FIG. 4 is another perspective sectional view of the auto-injector of FIG. 3, and



FIG. 5 is a detail view of the distal end of the auto-injector with a delay box,



FIG. 6 is a detailed view of the proximal end of the autoinjector showing the cap and needle shield remover.





Corresponding parts are marked with the same reference symbols in all figures.


DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS


FIG. 1 shows two longitudinal sections in different section planes of an auto-injector 1, the different section planes approximately 90° rotated to each other. The auto-injector 1 comprises an elongate housing 2. A syringe 3, e.g. a Hypak syringe, with a hollow needle 4 is arranged in a proximal part of the auto-injector 1. When the auto-injector 1 or the syringe 3 is assembled a protective needle shield 5 is attached to the needle 4. A stopper 6 is arranged for sealing the syringe 3 distally and for displacing a liquid medicament M through the hollow needle 4. The syringe 3 is held in a tubular syringe carrier 7 and supported at its proximal end therein. A single compression spring 8 is arranged in a distal part of the auto-injector 1. A plunger 9 is arranged for forwarding the spring force of the compression spring 8.


Inside the housing 2 a retraction sleeve 10 is slidably arranged. Before the injection is triggered as shown in FIG. 1 the retraction sleeve 10 is in a maximum proximal position and prevented from moving in distal direction D by means of stops 11 caught behind latches 12 in the housing 2. A distal end of the compression spring 8 bears against an end face 13 of the retraction sleeve 10. Due to the stops 11 and latches 12 the force of the compression spring 8 is thus reacted into the housing 2. The proximal end of the compression spring 8 bears against a decoupling member 14 arranged around the plunger 9. Distally from the end face 13 the retraction sleeve has two or more resilient arms 15 for holding a stud 16 and keeping it from being moved in proximal direction P. The stud 16 is arranged at the distal end of the plunger 9. The stud 16 and the resilient arms 15 have corresponding ramp features for pushing the resilient arms 15 apart in order to allow the stud 16 and the plunger 9 to move in proximal direction P.


The decoupling member 14 comprises a thrust face 17 for bearing against a proximal end of the compression spring 8. Proximally from the thrust face 17 two or more resilient decoupling arms 18 are provided at the decoupling member 14, the decoupling arms 18 having inner ramped surfaces bearing against a first shoulder 19 in the plunger 9 in proximal direction P. The resilient decoupling arms 18 are supported by an inner wall of the retraction sleeve 10 in this situation so they cannot flex outward and slip past the first shoulder 19.


A trigger button 20 is arranged at the distal end D of the auto-injector 1. The trigger button 20 may be pushed in proximal direction P in order to start an injection. As long as the trigger button 20 is not pushed the resilient arms 15 are caught between two or more retainers 21 arranged at the trigger button 20 so the resilient arms 15 cannot flex outward and the stud 16 although proximally biased by the compression spring 8 cannot slip through.


The syringe carrier 7 is engaged for joint axial movement with a syringe holder 22 which is slidably arranged in the retraction sleeve 10. The syringe holder 22 is provided with two or more resilient syringe holder arms 23 arranged distally. The syringe holder arms 23 have a respective inclined surface for bearing against a second shoulder 24 in the plunger 9 arranged proximally from the first shoulder 19. In the initial position shown in FIG. 1 the syringe holder arms 23 are supported by an inner surface of the housing 2 so they cannot flex outward and the second shoulder 24 cannot slip through. In order to support the syringe holder arms 23 at the housing 2 a respective number of apertures are provided in the retraction sleeve 10.



FIG. 1 shows the auto-injector 1 as-delivered with a cap 25 screwed onto to the proximal end P of the auto-injector 1. FIG. 6 shows details of the proximal end P with the cap 25. The cap 25 comprises a sheet metal clip 26 with two or more barbs 27 extending through an orifice into the proximal end P of the auto-injector 1. The sheet metal clip 26 is mounted to the cap 25 for joint axial movement with respect to a longitudinal axis of the auto-injector 1. However, the sheet metal clip 26 may rotate independently from the cap 25. This may be achieved by attaching the sheet metal clip 26 with a hole in its base onto a pin protruding inwardly from the cap 25 and deforming the pin to form a mushroom-shaped closing head 28 so as to prevent the sheet metal clip 26 from being removed while allowing some clearance for the sheet metal clip 26 to rotate. When the cap 25 is screwed onto the proximal P end of the auto-injector 1 the barbs 27 are pushed down the protective needle shield 5 and snap into a circumferential notch arranged in the protective needle shield 5 or behind a shoulder thereof.


When a user wants to operate the auto-injector 1 the first step is to unscrew the cap 25. Thus the barbs 27 pull the protective needle shield 5 off the syringe 3 in proximal direction P and through the orifice making the syringe 3 ready to be used.


A safety button 29 is arranged laterally at the distal part of the housing 2. The safety button 29 serves for interlocking with the trigger button 20 in a manner to prevent the trigger button 20 from being inadvertently operated without the safety button 29 being released from a first blocking position.


Consequently, in order to operate the trigger button 20 the safety button 29 has to be pushed transversally with respect to the longitudinal axis against the force of a spring element 30 which is formed in the safety button 29. The safety button 29 is pivoted in the middle so pushing the proximal end of the safety button 29 inward pulls an interlock 31 at its proximal end obstructing the trigger button 20 outward so the trigger button 20 can be pushed.


When the trigger button 20 is pushed the retainers 21 are pushed in proximal direction P so the resilient arms 15 are allowed to flex outward. Under load of the compression spring 8 the inclined surfaces of the stud 16 force the resilient arms 15 apart until the stud 16 can slip through.


The second shoulder 24 pushes the syringe holder 22, syringe carrier 7 and syringe 3 forward while no load is exerted onto the stopper 6. The hollow needle 4 appears from the proximal end P and is inserted into an injection site, e.g. a patient's skin.


The forward movement continues until the syringe holder 22 bottoms out at a first abutment 32 in the housing 2 (see FIG. 2). The travel from the initial position (cf. FIG. 1) up to this point defines an injection depth, i.e. needle insertion depth.


When the syringe holder 22 has nearly bottomed out the resilient syringe holder arms 23 have reached a widened portion 2.1 of the housing 2 where they are no longer supported by the inner wall of the housing 2. However, since the force required to insert the needle 4 is relatively low the second shoulder 24 will continue to drive forward the syringe holder 22 until proximal travel is halted at the first abutment 32. At this point the syringe holder arms 23 are flexed out by the continued force of the second shoulder 24 and allow it to slip through. Now the plunger 9 no longer pushes against the syringe holder 22 but against the stopper 6 for expelling the medicament M from the syringe 3 and injecting it into or through the patient's skin.


When the stopper 6 has nearly bottomed out in the syringe 3 (cf. FIG. 2) the decoupling member 14 has reached a position where it pushes against the latches 12 in a manner to decouple the retraction sleeve 10 from the housing 2, so the retraction sleeve 10 may slide in distal direction D. Thus the compression spring 8 is no longer grounded with its distal end in the housing 2. Instead, as soon as the decoupling member 14 has bottomed out at a second abutment 33 the proximal end of the compression spring 8 gets grounded in the housing while the distal end is pulling the retraction sleeve 10 in distal direction D.


Just before the decoupling member 14 decouples the retraction sleeve 10 from the housing 2 the decoupling arms 18 reach an aperture 34 in the retraction sleeve 10 (see FIG. 4) so they are no longer kept from being flexed outward. The decoupling arms 18 are thus pushed outward by the first shoulder 19 pushing against its ramped surfaces so the first shoulder 19 slips through in distal direction as soon as the decoupling member 14 has hit the second abutment 33.


The syringe holder 22 is taken along in distal direction D by the retraction sleeve 10, e.g. by a front face 35. Thus the syringe 3 and needle 4 are retracted into a safe position inside the housing 2, e.g. into the initial position. The plunger 9, no longer bearing against the decoupling arms 18 is pulled back too.


In the distal part of the auto-injector 1 a delay box 36 is arranged (see FIG. 5 for details). The delay box 36 comprises a circumferential outer wall 37 with a back collar 38 attached to the housing 2 and a circumferential inner wall 39 with a front collar 40 attached to the retraction sleeve 10. A volume between the outer wall 37 and inner wall 39 is filled with a viscous fluid, such as silicon grease. As the retraction sleeve 10 is moved in distal direction D the inner wall 39 glides along the outer wall 37 wherein the back collar 38 and front collar 40 increasingly reduce the volume. One or more holes (not shown) provided in a part of the delay box 36 allow the viscous fluid to be pushed out as the volume decreases. The force required to do this slows down the motion of the retraction sleeve 10.


The retraction sleeve 10 is released by the decoupling member 14 from the housing 2 a certain amount of time or travel before the stopper 6 bottoms out in the syringe 3 and the distal motion of the retraction sleeve 10 begins. The motion of the retraction sleeve 10 is slowed down by the delay box 36. Due to a gap 41 between the front face 35 and the syringe holder 22 the retraction sleeve 10 is not yet dragging the syringe back in distal direction D. The plunger 9 is still pushing against the stopper 6 and expelling residual medicament M. As the stopper 6 hits the proximal end of the syringe 3 the stopper 6 and plunger 9 stop while the retraction sleeve 10 is still slowly moving back in distal direction D. The apertures 34 now meet the decoupling arms 18 allowing them to flex out and the plunger 9 to come clear. The retraction sleeve 10 has now travelled back far enough to close the gap 41 so the syringe holder 22, syringe carrier 7, syringe 3, needle 4 and plunger 9 are dragged back in distal direction D.


The cap 25 and the delay box 36 are not restricted to be used with the auto-injector 1 shown in the embodiments. Instead the cap 25 may be combined with any kind of auto-injector with the needle hidden in the housing prior to an injection. The delay box may be combined with any kind of auto-injector for ensuring full delivery of the syringe's contents and reliable triggering of the retraction, irrespective of the spring means or driving means used in the respective auto-injector.


The housing 2 may have at least one viewing window for inspecting the syringe 3.


The auto-injector 1 may preferably be used for subcutaneous or intra-muscular injection, particularly for delivering one of an analgetic, an anticoagulant, insulin, an insulin derivate, heparin, Lovenox, a vaccine, a growth hormone, a peptide hormone, a proteine, antibodies and complex carbohydrates.


The aforementioned arrangement for coupling the plunger (9) to either, the syringe (3) or the stopper (6), may be applied in any auto-injector having a plunger for forwarding a force of a drive means to a syringe with a stopper. The primary advantage of this arrangement ensures the load from the drive means is not transferred directly to the stopper until the needle is inserted in the patient, thus avoiding a wet injection. The arrangement comprises the syringe holder (22) and associated syringe holder arms (23), a shoulder (e.g. the second shoulder 24) on the plunger (9), the support of the holder arms (23) by an inner surface in order to prevent them from flexing out in a first position and, a widened portion (2.1) for allowing them to flex radially and to disconnect from the plunger when in a more proximal position. The spring means or other drive means, the ability to retract the syringe or to forward a needle shroud after injection and other features described herein are not required for the prevention of a wet injection.


LIST OF REFERENCES






    • 1 auto-injector


    • 2 housing


    • 2.1 widened portion


    • 3 syringe


    • 4 hollow needle


    • 5 protective needle shield


    • 6 stopper


    • 7 syringe carrier


    • 8 spring means, compression spring


    • 8.1 distal end


    • 8.2 proximal end


    • 9 plunger


    • 10 retraction sleeve


    • 11 stop


    • 12 latch


    • 13 end face


    • 14 decoupling member


    • 15 resilient arm


    • 16 stud


    • 17 thrust face


    • 18 decoupling arm


    • 19 first shoulder


    • 20 activating means, trigger button


    • 21 retainer


    • 22 syringe holder


    • 23 syringe holder arm


    • 24 second shoulder


    • 25 cap


    • 26 sheet metal clip


    • 27 barb


    • 28 closing head


    • 29 safety button


    • 30 spring element


    • 31 interlock


    • 32 first abutment


    • 33 second abutment


    • 34 aperture


    • 35 front face


    • 36 delay box


    • 37 outer wall


    • 38 back collar


    • 39 inner wall


    • 40 front collar


    • 41 gap

    • D distal end, distal direction

    • M medicament

    • P proximal end, proximal direction




Claims
  • 1. An auto-injector comprising: a cylindrical housing containing a syringe that contains a medicament, the syringe comprising a stopper slidably disposed within a body of the syringe, the stopper forming a fluid tight seal with the body of the syringe, the cylindrical housing comprising at least one window for viewing the medicament within the syringe;a plunger rod configured to engage the stopper for dispensing the medicament from the syringe;a compression drive spring surrounding the plunger rod and configured to bias the plunger rod in a proximal direction to dispense the medicament from the syringe;a sleeve comprising a resilient arm configured to be releasably coupled to the plunger rod, the resilient arm having an inner ramped surface, the sleeve having a first state in which the inner ramped surface of the resilient arm is held in engagement with a surface of the plunger rod to prevent the plunger rod from moving proximally relative to the sleeve under a force of the compression drive spring, and the sleeve having a second state in which the inner ramped surface of the resilient arm is outwardly deflected out of engagement with the surface of the plunger rod to allow the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament;a slidable member configured to slide axially relative to the cylindrical housing from a first position in which the slidable member extends from an end of the cylindrical housing by a first distance to a second position in which the slidable member extends from the end of the cylindrical housing by a second distance, the first distance being greater than the second distance; anda syringe carrier disposed within the cylindrical housing, the syringe carrier defining a cavity in which the syringe is disposed, the syringe carrier comprising an inwardly angled protrusion that is located at a proximal end of the syringe carrier and that is engaged with a proximal end of the body of the syringe to hold the syringe within the syringe carrier,wherein a distal end of the compression drive spring is disposed within a recess of the sleeve.
  • 2. The auto-injector of claim 1, wherein when the slidable member is in the second position the sleeve can change from the first state to the second state.
  • 3. The auto-injector of claim 1, wherein the syringe carrier is sized such that a distal flange of the syringe is distally spaced apart from a sidewall of the syringe carrier while the proximal end of the body of the syringe is engaged with the inwardly angled protrusion of the syringe carrier.
  • 4. The auto-injector of claim 3, wherein the syringe carrier is tubular.
  • 5. The auto-injector of claim 1, wherein the cylindrical housing has a unitary construction.
  • 6. The auto-injector of claim 1, wherein the syringe is a glass syringe.
  • 7. The auto-injector of claim 1, wherein the resilient arm of the sleeve is a first resilient arm of the sleeve and the sleeve comprises a second resilient arm.
  • 8. An auto-injector comprising: a housing configured to contain a syringe containing a medicament, the syringe comprising a stopper slidably disposed within the syringe, the housing comprising at least one window for viewing the medicament within the syringe from an exterior of the auto-injector;a plunger rod configured to engage the stopper for dispensing the medicament from the syringe;a compression drive spring surrounding the plunger rod and configured to bias the plunger rod in a proximal direction to dispense the medicament from the syringe;a sleeve comprising a resilient arm configured to be releasably coupled to the plunger rod, the resilient arm having an inner ramped surface, the sleeve having a first state in which the inner ramped surface of the resilient arm is held in engagement with the plunger rod to prevent the plunger rod from moving proximally relative to the sleeve under a force of the compression drive spring, and the sleeve having a second state in which the inner ramped surface of the resilient arm is outwardly deflected out of engagement with the plunger rod to allow the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament; anda syringe carrier disposed within the housing, the syringe carrier defining a cavity for holding the syringe, the syringe carrier comprising an inwardly angled protrusion located at a proximal end of the syringe carrier and for engaging with a proximal end of the syringe to hold the syringe within the syringe carrier.
  • 9. The auto-injector of claim 8, wherein a distal end of the compression drive spring is disposed within a recess of the sleeve.
  • 10. The auto-injector of claim 8, comprising a slidable member configured to slide axially relative to the housing from a first position in which the slidable member extends from an end of the housing by a first distance to a second position in which the slidable member extends from the end of the housing by a second distance, the first distance being greater than the second distance.
  • 11. The auto-injector of claim 10, wherein when the slidable member is in the second position the sleeve can change from the first state to the second state.
  • 12. The auto-injector of claim 8, wherein the syringe carrier is sized such that a distal flange of the syringe is distally spaced apart from a sidewall of the syringe carrier while the proximal end of the syringe is engaged with the inwardly angled protrusion of the syringe carrier.
  • 13. The auto-injector of claim 8, wherein the syringe carrier is tubular.
  • 14. The auto-injector of claim 8, wherein the housing is cylindrical and has a unitary construction.
  • 15. An auto-injector comprising: a cylindrical housing containing a syringe that contains a medicament, the syringe comprising a stopper slidably disposed within a body of the syringe, the stopper forming a fluid tight seal with the body of the syringe, the cylindrical housing comprising at least one window for viewing the medicament within the syringe;a plunger rod configured to engage the stopper for dispensing the medicament from the syringe;a compression drive spring surrounding at least a distal portion of the plunger rod and configured to bias the plunger rod in a proximal direction to dispense the medicament from the syringe;a sleeve comprising a resilient arm configured to be releasably coupled to the plunger rod, the resilient arm having an inner ramped surface, the sleeve having a first state in which the inner ramped surface of the resilient arm is held in engagement with a surface of the plunger rod to prevent the plunger rod from moving proximally relative to the sleeve under a force of the compression drive spring, and the sleeve having a second state in which the inner ramped surface of the resilient arm is outwardly deflected out of engagement with the surface of the plunger rod to allow the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament;a cylindrical member disposed within the cylindrical housing, the cylindrical member and the sleeve configured to move relative to each other from a first position in which the cylindrical member contacts the sleeve to prevent the resilient arm from deflecting outward to a second position in which the cylindrical member and the resilient arm have moved relative to each other to allow the resilient arm of the sleeve to deflect outward, wherein moving the cylindrical member and the sleeve relative to each other from the first position to the second position changes the sleeve from the first state to the second state thereby allowing the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament; anda syringe carrier disposed within the cylindrical housing, the syringe carrier defining a cavity in which the syringe is disposed, the syringe carrier comprising an inwardly angled protrusion that is located at a proximal end of the syringe carrier and that is engaged with a proximal end of the body of the syringe to hold the syringe within the syringe carrier,wherein a distal end of the compression drive spring is disposed within a recess of the sleeve.
  • 16. The auto-injector of claim 15, wherein the syringe carrier is sized such that a distal flange of the syringe is distally spaced apart from a sidewall of the syringe carrier while the proximal end of the body of the syringe is engaged with the inwardly angled protrusion of the syringe carrier.
  • 17. The auto-injector of claim 16, wherein the syringe carrier is tubular.
  • 18. The auto-injector of claim 15, wherein the cylindrical member contacts an outer surface of the resilient arm to prevent the resilient arm from deflecting outward when the cylindrical member and the sleeve are in the first position relative to each other.
  • 19. The auto-injector of claim 15, wherein the cylindrical housing has a unitary construction.
  • 20. The auto-injector of claim 15, further comprising a cap removably attached to a proximal end of the auto-injector, the cap being configured to engage a needle shield attached to a proximal end of the syringe and covering an injection needle attached to the syringe to remove the needle shield from the injection needle.
  • 21. The auto-injector of claim 20, wherein the cap is configured such that a removal of the cap from the auto-injector removes the needle shield from the injection needle.
  • 22. An auto-injector comprising: a housing configured to receive a syringe containing a medicament, the syringe comprising a stopper slidably disposed within the syringe, the housing comprising at least one window for viewing the medicament within the syringe;a plunger rod configured to engage the stopper for dispensing the medicament from the syringe;a compression drive spring surrounding at least a distal portion of the plunger rod and configured to bias the plunger rod in a proximal direction to dispense the medicament from the syringe;a sleeve comprising a resilient arm configured to be releasably coupled to the plunger rod, the resilient arm having an inner ramped surface, the sleeve having a first state in which the inner ramped surface of the resilient arm is held in engagement with the plunger rod to limit the plunger rod from moving proximally relative to the sleeve under a force of the compression drive spring, and the sleeve having a second state in which the inner ramped surface of the resilient arm has outwardly deflected out of engagement with the plunger rod to allow the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament; anda cylindrical member disposed within the housing, the cylindrical member and the sleeve configured to move relative to each other to allow the sleeve to change from the first state to the second state.
  • 23. The auto-injector of claim 22, comprising a syringe carrier disposed within the housing, the syringe carrier defining a cavity for receiving the syringe.
  • 24. The auto-injector of claim 23, wherein the syringe carrier comprises an inwardly angled protrusion located at a proximal end of the syringe carrier for engaging to a proximal end of the syringe to hold the syringe within the syringe carrier.
  • 25. The auto-injector of claim 24, wherein the syringe carrier is sized such that a distal flange of the syringe is distally spaced apart from a sidewall of the syringe carrier while the proximal end of the syringe is engaged with the inwardly angled protrusion of the syringe carrier.
  • 26. The auto-injector of claim 22, wherein the cylindrical member and the sleeve are configured to move relative to each other from a first position in which the cylindrical member contacts the sleeve to prevent the resilient arm from deflecting outward.
  • 27. The auto-injector of claim 26, wherein the cylindrical member and the sleeve are configured to move relative to each other to a second position in which the cylindrical member and the resilient arm have moved relative to each other to allow the resilient arm of the sleeve to deflect outward.
  • 28. The auto-injector of claim 27, wherein moving the cylindrical member and the sleeve relative to each other from the first position to the second position changes the sleeve from the first state to the second state thereby allowing the plunger rod to move proximally relative to the sleeve under the force of the compression drive spring to dispense the medicament.
  • 29. The auto-injector of claim 22, further comprising a cap removably attached to a proximal end of the auto-injector, the cap being configured to engage a needle shield attached to a proximal end of the syringe and covering an injection needle attached to the syringe to remove the needle shield from the injection needle.
  • 30. The auto-injector of claim 29, wherein the cap is configured such that a removal of the cap from the auto-injector removes the needle shield from the injection needle.
Priority Claims (1)
Number Date Country Kind
10153999 Feb 2010 EP regional
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 17/706,380, filed Mar. 28, 2022, which is a continuation of U.S. patent application Ser. No. 17/453,601, filed on Nov. 4, 2021, which is a continuation of U.S. patent application Ser. No. 16/276,366, filed Feb. 14, 2019, now U.S. Pat. No. 11,197,958, which is a continuation of U.S. patent application Ser. No. 14/995,964, filed Jan. 14, 2016, now U.S. Pat. No. 10,232,116, which is a continuation of U.S. patent application Ser. No. 13/579,435, filed Feb. 25, 2013, now U.S. Pat. No. 9,248,245, which is a 35 U.S.C. 371 National Application of PCT/EP2011/052301, filed Feb. 16, 2011, and claims priority to European Patent Application No. 10153999.7, filed Feb. 18, 2010 and U.S. Patent Application No. 61/412,086, filed Nov. 10, 2010, the entire contents of which are incorporated entirely herein by reference.

US Referenced Citations (167)
Number Name Date Kind
5137516 Rand Aug 1992 A
5267963 Bachynsky Dec 1993 A
6004297 Steenfeldt-Jensen et al. Dec 1999 A
6277099 Strowe et al. Aug 2001 B1
6454743 Weber Sep 2002 B1
6620137 Kirchhofer et al. Sep 2003 B2
7195616 Diller et al. Mar 2007 B2
7291132 DeRuntz et al. Nov 2007 B2
7297135 Jeffrey Nov 2007 B2
7341575 Rice et al. Mar 2008 B2
7597685 Olson Oct 2009 B2
7666164 Giambattista et al. Feb 2010 B2
7678085 Graf Mar 2010 B2
7717877 Lavi et al. May 2010 B2
7771397 Olson Aug 2010 B1
7771398 Knight et al. Aug 2010 B2
7811261 Rubinstein et al. Oct 2010 B2
7918824 Bishop et al. Apr 2011 B2
7976494 Kohlbrenner et al. Jul 2011 B2
7988675 Gillespie et al. Aug 2011 B2
8038649 Kronestedt Oct 2011 B2
8048037 Kohlbrenner et al. Nov 2011 B2
8062255 Brunnberg et al. Nov 2011 B2
8083711 Enggaard Dec 2011 B2
8323238 Cronenberg et al. Dec 2012 B2
8357125 Grunhut et al. Jan 2013 B2
8361025 Lawlis et al. Jan 2013 B2
8366680 Raab Feb 2013 B2
8376993 Cox et al. Feb 2013 B2
8376997 Hogdahl et al. Feb 2013 B2
8403883 Fayyaz et al. Mar 2013 B2
8409138 James et al. Apr 2013 B2
8409141 Johnsen et al. Apr 2013 B2
8409148 Fiechter et al. Apr 2013 B2
8414533 Alexandersson Apr 2013 B2
8439864 Galbraith et al. May 2013 B2
8491538 Kohlbrenner et al. Jul 2013 B2
8568359 Carrel et al. Oct 2013 B2
8579866 Morgan et al. Nov 2013 B2
8617109 Kronestedt et al. Dec 2013 B2
8617124 Wieselblad et al. Dec 2013 B2
8632507 Bartha Jan 2014 B2
8684969 Moller et al. Apr 2014 B2
8708973 Holmqvist Apr 2014 B2
8734394 Adams et al. May 2014 B2
8734402 Sharp et al. May 2014 B2
8758292 Tschirren et al. Jun 2014 B2
8808250 Ekman et al. Aug 2014 B2
8808251 Raab et al. Aug 2014 B2
8821451 Daniel Sep 2014 B2
8834431 Kohlbrenner et al. Sep 2014 B2
8840591 Raab et al. Sep 2014 B2
8882723 Smith et al. Nov 2014 B2
8911410 Ekman et al. Dec 2014 B2
8911411 Nielsen Dec 2014 B2
8939934 Brereton et al. Jan 2015 B2
8945063 Wotton et al. Feb 2015 B2
8956331 Johnsen et al. Feb 2015 B2
8961473 Heald Feb 2015 B2
8968256 Raab Mar 2015 B2
8968258 Nzike et al. Mar 2015 B2
8992484 Radmer et al. Mar 2015 B2
8992487 Eich et al. Mar 2015 B2
9005160 Karlsson et al. Apr 2015 B2
9011386 Kronestedt et al. Apr 2015 B2
9011387 Ekman et al. Apr 2015 B2
9022991 Moeller May 2015 B1
9022994 Moser et al. May 2015 B2
9044548 Miller et al. Jun 2015 B2
9044553 James et al. Jun 2015 B2
9057369 Kohlbrenner et al. Jun 2015 B2
9061104 Daniel Jun 2015 B2
9067024 Roberts et al. Jun 2015 B2
9089652 Nzike et al. Jul 2015 B2
9108002 Markussen Aug 2015 B2
9125988 Karlsson Sep 2015 B2
9132235 Holmqvist Sep 2015 B2
9199038 Daniel Dec 2015 B2
9205199 Kemp et al. Dec 2015 B2
9216256 Olson et al. Dec 2015 B2
9233213 Olson et al. Jan 2016 B2
9233214 Kemp et al. Jan 2016 B2
9233215 Hourmand et al. Jan 2016 B2
9242044 Markussen Jan 2016 B2
9248245 Ekman et al. Feb 2016 B2
9272098 Hourmand et al. Mar 2016 B2
9283326 Kemp et al. Mar 2016 B2
9283327 Hourmand et al. Mar 2016 B2
9283328 Dasbach Mar 2016 B2
9308327 Marshall et al. Apr 2016 B2
9333304 Brereton et al. May 2016 B2
9339607 Langley et al. May 2016 B2
9352088 Ekman et al. May 2016 B2
9358345 Brereton et al. Jun 2016 B2
9358351 Ekman et al. Jun 2016 B2
9393368 Nzike et al. Jul 2016 B2
9402957 Adams et al. Aug 2016 B2
9408976 Olson Aug 2016 B2
9408977 Butler et al. Aug 2016 B2
9408979 Veasey et al. Aug 2016 B2
9415165 Cowe Aug 2016 B2
9421336 Ekman et al. Aug 2016 B2
9427525 Barrow-Williams et al. Aug 2016 B2
9446196 Hourmand et al. Sep 2016 B2
9446201 Holmqvist Sep 2016 B2
9457149 Kemp et al. Oct 2016 B2
9457152 Raab et al. Oct 2016 B2
9492622 Brereton et al. Nov 2016 B2
9649441 Barrow-Williams et al. May 2017 B2
9662452 Daniel May 2017 B2
9867940 Holmqvist et al. Jan 2018 B2
9872961 Fourt et al. Jan 2018 B2
10118001 Fourt et al. Nov 2018 B2
10314981 Sampson et al. Jun 2019 B2
10350356 Hirschel et al. Jul 2019 B2
10350362 Dennis, Jr. et al. Jul 2019 B2
10363377 Atterbury et al. Jul 2019 B2
10420898 Daniel Sep 2019 B2
10569019 Hirschel et al. Feb 2020 B2
10799647 Hostettler et al. Oct 2020 B2
10881799 Hirschel et al. Jan 2021 B2
11197958 Ekman et al. Dec 2021 B2
11298462 Atterbury et al. Apr 2022 B2
11383044 Tschirren et al. Jul 2022 B2
11452821 Lafever et al. Sep 2022 B2
20020007154 Hansen et al. Jan 2002 A1
20020095120 Larsen et al. Jul 2002 A1
20030105430 Lavi et al. Jun 2003 A1
20040039336 Amark et al. Feb 2004 A1
20050101919 Brunnberg et al. May 2005 A1
20050165360 Stamp Jul 2005 A1
20050222539 Gonzales et al. Oct 2005 A1
20060129089 Stamp Jun 2006 A1
20060153693 Fiechter et al. Jul 2006 A1
20060287630 Hommann Dec 2006 A1
20070027430 Hommann Feb 2007 A1
20070112310 Lavi et al. May 2007 A1
20080147006 Brunnberg et al. Jun 2008 A1
20080262427 Hommann Oct 2008 A1
20080269692 James et al. Oct 2008 A1
20090012471 Harrison Jan 2009 A1
20100130930 Stamp et al. May 2010 A1
20100152655 Stamp Jun 2010 A1
20100185178 Sharp et al. Jul 2010 A1
20110054411 Dowds et al. Mar 2011 A1
20110282278 Stamp et al. Nov 2011 A1
20110319864 Beller et al. Dec 2011 A1
20120010575 Jones et al. Jan 2012 A1
20120041387 Bruggemann et al. Feb 2012 A1
20120053528 Bollenbach et al. Mar 2012 A1
20120172817 Bruggemann et al. Jul 2012 A1
20130035647 Veasey et al. Feb 2013 A1
20130041328 Daniel Feb 2013 A1
20130123710 Ekman et al. May 2013 A1
20130261556 Jones et al. Oct 2013 A1
20130274662 Hourmand et al. Oct 2013 A1
20130274677 Ekman et al. Oct 2013 A1
20130289525 Kemp et al. Oct 2013 A1
20130345643 Hourmand et al. Dec 2013 A1
20150273157 Kohlbrenner et al. Oct 2015 A1
20160089498 Daniel Mar 2016 A1
20180064875 Holmqvist Mar 2018 A1
20200139047 Hirschel et al. May 2020 A1
20210154407 Hirschel et al. May 2021 A1
20230022361 Heiniger et al. Jan 2023 A1
20240197997 Ekman et al. Jun 2024 A1
20240197998 Ekman et al. Jun 2024 A1
Foreign Referenced Citations (64)
Number Date Country
705345 Feb 2013 CH
705992 Jun 2013 CH
19819409 Nov 1999 DE
102005038933 Feb 2007 DE
202007000578 Mar 2007 DE
102005052502 May 2007 DE
0666084 Aug 1995 EP
0824923 Feb 1998 EP
0991441 Dec 2003 EP
2399634 Dec 2011 EP
2468334 Jun 2012 EP
2468335 Jun 2012 EP
2742962 Jun 2014 EP
3650064 May 2020 EP
3381490 Sep 2020 EP
2654938 May 1991 FR
2438592 Dec 2007 GB
H08-502180 Mar 1996 JP
2002-528182 Sep 2002 JP
2007-500530 Jan 2007 JP
WO 1994004103 Mar 1994 WO
WO 1999053979 Oct 1999 WO
WO 2000024441 May 2000 WO
WO 2002047746 Jun 2002 WO
WO 2003062672 Jul 2003 WO
WO 2005009515 Feb 2005 WO
WO 2005070481 Aug 2005 WO
WO 2005097238 Oct 2005 WO
WO 2005115507 Dec 2005 WO
WO 2006057604 Jun 2006 WO
WO 2006079064 Jul 2006 WO
WO 2007083115 Jul 2007 WO
WO 2007099044 Sep 2007 WO
WO 2007129324 Nov 2007 WO
WO 2008059385 May 2008 WO
WO 2008116688 Oct 2008 WO
WO 2008155377 Dec 2008 WO
WO 2009019440 Feb 2009 WO
WO 2009040601 Apr 2009 WO
WO 2009040603 Apr 2009 WO
WO 2009040607 Apr 2009 WO
WO 2009040672 Apr 2009 WO
WO 2009062508 May 2009 WO
WO 2009081103 Jul 2009 WO
WO 2010007395 Jan 2010 WO
WO 2010063707 Jun 2010 WO
WO 2010136077 Dec 2010 WO
WO 2011012903 Feb 2011 WO
WO 2011043714 Apr 2011 WO
WO 2011075101 Jun 2011 WO
WO 2011109205 Sep 2011 WO
WO 2011111006 Sep 2011 WO
WO 2011117592 Sep 2011 WO
WO 2011123024 Oct 2011 WO
WO 2011126439 Oct 2011 WO
WO 2012045350 Apr 2012 WO
WO 2012085024 Jun 2012 WO
WO 2019074788 Apr 2019 WO
WO 2020190529 Sep 2020 WO
WO 2021008839 Jan 2021 WO
WO 2021160540 Aug 2021 WO
WO 2021197804 Oct 2021 WO
WO 2022069617 Apr 2022 WO
WO 2022184388 Sep 2022 WO
Non-Patent Literature Citations (2)
Entry
International Preliminary Report on Patentability in Application No. PCT/EP2011/052301, dated Aug. 21, 2012, 6 pages.
International Search Report and Written Opinion in Application No. PCT/EP2011/052301, dated May 26, 2011, 9 pages.
Related Publications (1)
Number Date Country
20240238520 A1 Jul 2024 US
Provisional Applications (1)
Number Date Country
61412086 Nov 2010 US
Continuations (5)
Number Date Country
Parent 17706380 Mar 2022 US
Child 18622107 US
Parent 17453601 Nov 2021 US
Child 17706380 US
Parent 16276366 Feb 2019 US
Child 17453601 US
Parent 14995964 Jan 2016 US
Child 16276366 US
Parent 13579435 US
Child 14995964 US